SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Palisade Bio (PALI) Reports $14.6M Q3 Net Loss; Cash Runway Through Key Phase 2 Milestones

Palisade Bio reported a Q3 2026 net loss of $14.6M, compared with $2.9M in Q3 2025, and held $113.6M in cash at September 30, 2026. The company expects cash to fund operations through key Phase 2 milestones.Material DetailsContext by AI AnalystThis is an early-stage clinical development update: PAL…

PALI

Related stories